@article{31fccf4159824d2c93eadddd860ae56d,
title = "Circular-SWAT for deep learning based diagnostic classification of Alzheimer's disease: application to metabolome data",
abstract = "Background: Deep learning has shown potential in various scientific domains but faces challenges when applied to complex, high-dimensional multi-omics data. Alzheimer's Disease (AD) is a neurodegenerative disorder that lacks targeted therapeutic options. This study introduces the Circular-Sliding Window Association Test (c-SWAT) to improve the classification accuracy in predicting AD using serum-based metabolomics data, specifically lipidomics. Methods: The c-SWAT methodology builds upon the existing Sliding Window Association Test (SWAT) and utilizes a three-step approach: feature correlation analysis, feature selection, and classification. Data from 997 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) served as the basis for model training and validation. Feature correlations were analyzed using Weighted Gene Co-expression Network Analysis (WGCNA), and Convolutional Neural Networks (CNN) were employed for feature selection. Random Forest was used for the final classification. Findings: The application of c-SWAT resulted in a classification accuracy of up to 80.8% and an AUC of 0.808 for distinguishing AD from cognitively normal older adults. This marks a 9.4% improvement in accuracy and a 0.169 increase in AUC compared to methods without c-SWAT. These results were statistically significant, with a p-value of 1.04 × 10ˆ-4. The approach also identified key lipids associated with AD, such as Cer(d16:1/22:0) and PI(37:6). Interpretation: Our results indicate that c-SWAT is effective in improving classification accuracy and in identifying potential lipid biomarkers for AD. These identified lipids offer new avenues for understanding AD and warrant further investigation. Funding: The specific funding of this article is provided in the acknowledgements section.",
keywords = "Alzheimer's disease, Deep learning, Lipidomics, Machine learning, Metabolomics",
author = "Taeho Jo and Junpyo Kim and Paula Bice and Kevin Huynh and Tingting Wang and Matthias Arnold and Meikle, {Peter J.} and Corey Giles and Rima Kaddurah-Daouk and Saykin, {Andrew J.} and Kwangsik Nho and {for the Alzheimer's Disease Metabolomics Consortium (ADMC) the Alzheimer{\textquoteright}s Disease Neuroimaging Initiative (ADNI)}",
note = "Funding Information: Funding for ADMC (Alzheimer's Disease Metabolomics Consortium, led by Dr R.K.-D. at Duke University) was provided by the National Institute on Aging grants 1U19AG063744, 1R01AG069901-01A1, U01AG061357, P30AG10161, P30AG72975, R01AG15819, R01AG17917, U01AG46152, U01AG61356, RF1AG058942, RF1AG059093, and U01AG061359, a component of the Accelerating Medicines Partnership for AD (AMP-AD) Target Discovery and Preclinical Validation Project ( https://www.nia.nih.gov/research/dn/amp-ad-target-discovery-and-preclinical-validation-project ) and the National Institute on Aging, a component of the M 2 OVE-AD Consortium (Molecular Mechanisms of the Vascular Etiology of AD—Consortium https://www.nia.nih.gov/news/decoding-molecular-ties-between-vascular-disease-and-alzheimers ). Funding Information: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) ( National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging , the National Institute of Biomedical Imaging and Bioengineering , and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Funding Information: Additional support for data analysis was provided in part by grants: AARG 22-974053, P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, U01 AG068057, U01 AG072177, R01 LM012535, R01 AG069901 and R03 AG063250. Publisher Copyright: {\textcopyright} 2023 The Author(s)",
year = "2023",
month = nov,
doi = "10.1016/j.ebiom.2023.104820",
language = "English",
volume = "97",
journal = "EBioMedicine",
issn = "2352-3964",
publisher = "The Lancet Publishing Group",
}